Latest News - Biogen
Top Corporates Hub
Biogen
Barclays Initiates Coverage On Biogen with Equal-Weight Rating, Announces Price Target of $185
20.02.2026 10:47
Barclays analyst Emily Field initiates coverage on Biogen (NASDAQ:BIIB) with a Equal-Weight rating and announces Price Target of $185.
What Are Wall Street Analysts' Target Price for Biogen Stock?
16.02.2026 11:17
Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook
10.02.2026 12:09
Biogen (NasdaqGS:BIIB) received Breakthrough Therapy Designation from the FDA for litifilimab in cutaneous lupus erythematosus. The company reported phase 2/3 trial results for high dose nusinersen in spinal muscular atrophy. Both updates relate to Biogen's drug pipeline in neurological and autoimmune diseases. For investors watching Biogen, these updates go to the heart of what drives the company: its drug pipeline. Biogen is known for treatments targeting neurological and related...
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next
10.02.2026 06:06
Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted with a strong full-year net income of US$1.29 billion. Alongside earnings, Biogen highlighted progress in its neurology pipeline, including FDA Breakthrough Therapy Designation for litifilimab in cutaneous lupus and ongoing review of a high-dose SPINRAZA regimen for spinal muscular atrophy. Next,...
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
09.02.2026 02:00
TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
07.02.2026 08:30
Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.
Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch
06.02.2026 00:00
Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Friday, February 6, including earnings results from Under Armour (UAA, UA), Biogen (BIIB), and Philip Morris (PM); commentary from Federal Reserve Vice Chair Philip Jefferson; and Liftoff Mobile making its public debut on the Nasdaq, trading under the ticker LFTO. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
05.02.2026 03:02
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Friday before market open. Here’s what investors should know.
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04.02.2026 12:30
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neurofilament, than the 12 mg regimen CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating
Is Biogen (BIIB) Pricing Reflect Recent 1 Year Rebound And Long Term Weakness?
01.02.2026 12:11
If you are wondering whether Biogen's current share price gives you good value for the risk you are taking, you are not alone. Over the last year the stock returned 25.0%. The 3 year and 5 year returns were declines of 36.6% and 32.1%, alongside a 7 day return of 4.8%, and a 30 day and year to date return of 1.2%. Recent attention on Biogen has centered on its position in pharmaceuticals and biotech, with investors weighing how its product portfolio and pipeline might justify the current...
Biogen’s Litifilimab Milestone Puts Spotlight On Valuation And Growth Prospects
01.02.2026 00:18
Biogen's investigational drug litifilimab has received FDA Breakthrough Therapy Designation for treating cutaneous lupus erythematosus. The designation highlights litifilimab's potential to address an unmet need in a chronic autoimmune skin condition with limited treatment options. This represents a significant milestone in Biogen's drug pipeline that could speed up development timelines for this program. For investors watching Biogen, ticker NasdaqGS:BIIB, this update on litifilimab adds a...
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
30.01.2026 15:00
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
22.01.2026 14:00
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference
13.01.2026 08:02
Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
12.01.2026 04:05
The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application
06.01.2026 14:13
Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
06.01.2026 01:00
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why
23.12.2025 03:12
In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound
18.12.2025 00:16
Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...